Results 1 to 10 of about 2,022,996 (246)

Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy [PDF]

Frontiers in Oncology, 2021
Immunotherapy has significantly improved the clinical outcome of patients with cancer. However, the immune response rate varies greatly, possibly due to lack of effective biomarkers that can be used to distinguish responders from non-responders. Recently,
Peipei Wang, Yueyun Chen, Chun Wang
doaj   +7 more sources

Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer [PDF]

Frontiers in Immunology
IntroductionGastric cancer is one of the most diagnosed cancers and a major contributor to cancer-related death in China. Recent studies have demonstrated the failure of tumor mutational burden (TMB) in predictive accuracy. Here, we aimed to evaluate the
Tingting Lu, Jingyi Cao, Peng Liu, Xiaoxin Pan, Yiming Shen, Jian Wang, Zhida Chen, Yi Liu, Fenglin Zhang, Haiya Zhang, Gan Zhang, Yi Wang, Ji Wan, Hongqing Xi   +13 more
doaj   +7 more sources

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth [PDF]

Translational Oncology, 2020
The immunogenic clonal-fraction threshold in heterogeneous solid-tumor required to induce effective bystander-killing of non-immunogenic subclones is unknown.
Manisit Das, Xuefei Zhou, Yun Liu, Anirban Das, Benjamin G. Vincent, Jingjing Li, Rihe Liu, Leaf Huang   +7 more
doaj   +2 more sources

CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden [PDF]

Journal for ImmunoTherapy of Cancer, 2023
Background Expression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8+ T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify neoantigen-specific T cells in colorectal cancers (CRCs ...
Sjoerd H van der Burg, Rebekka Duhen, Thomas Duhen, Marieke E Ijsselsteijn, Ruud van der Breggen, Koen C M J Peeters, Noel F C C de Miranda, Els M E Verdegaal, Dina Ruano, Manon van der Ploeg, Jitske van den Bulk, Arantza Fariña-Sarasqueta   +11 more
doaj   +2 more sources

Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report

Journal for ImmunoTherapy of Cancer, 2020
Background Collecting duct carcinoma (CDC) of the kidney is a rare and highly aggressive malignant tumor with the worst prognosis among all renal cancers.
Wei Zhang, Xiaoping Su, Yongyi Zeng, Zhenli Li, Youshi Zheng, Yingchao Wang, Geng Chen, Liman Qiu, Kun Ke, Zhixiong Cai, Jingfeng Liu, Xiaolong Liu   +11 more
doaj   +2 more sources

Neoantigen Quantity and Quality in Relation to Pancreatic Cancer Survival [PDF]

Frontiers in Medicine, 2022
IntroductionFactors underlying antitumor immunity in pancreatic cancer (PC) are poorly understood. We hypothesized that not neoantigen quantity, but quality, is related to immune cell infiltration and survival.MethodologyWe performed genomic and ...
Iris J. M. Levink, Lodewijk A. A. Brosens, Sander S. Rensen, Merel R. Aberle, Steven S. W. Olde Damink, Steven S. W. Olde Damink, Djuna L. Cahen, Sonja I. Buschow, Gwenny M. Fuhler, Maikel P. Peppelenbosch, Marco J. Bruno   +10 more
doaj   +4 more sources

Multiomics prediction and immunogenic validation of personalized neoantigens in cholangiocarcinoma patients [PDF]

Journal of Translational Medicine
Background Cholangiocarcinoma (CCA) is an aggressive biliary tract cancer with limited treatment options, underscoring the need for breakthrough precision therapies. Neoantigen-based therapy is a promising novel strategy for cancer treatment.
Baoluhe Zhang, Bao Jin, Xueshuai Wan, Xiao Liu, Xiang’an Wu, Jiali Xing, Yuxin Wang, Haifeng Xu, Yiyao Xu, Mei Guan, Yilei Mao, Yating Bai, Junqi Zhu, Qian Chen, Shunda Du   +14 more
doaj   +2 more sources

Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications [PDF]

npj Precision Oncology
Glioblastoma (GBM) poses unique challenges to immunotherapy, owing to its low tumor mutational burden, profound antigenic heterogeneity, and highly immunosuppressive microenvironment.
Cameron M. Hill, Chibueze D. Nwagwu, Angel O. Odukoya, Brian Hsueh, Anthony Z. Wang, Gavin P. Dunn   +5 more
doaj   +2 more sources

Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors

Genome Biology, 2023
Background Neoantigens are critical for anti-tumor immunity and have been long-envisioned as promising therapeutic targets. However, current neoantigen analyses mostly focus on single nucleotide variations (SNVs) and indel mutations and seldom consider ...
Yang Shi, Biyang Jing, Ruibin Xi
doaj   +1 more source

Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response

ImmunoInformatics, 2021
Response to cancer immunotherapies depends on the complex and dynamic interactions between T cell recognition and killing of cancer cells that are counteracted through immunosuppressive pathways in the tumor microenvironment.
Shuming Zhang, Chang Gong, Alvaro Ruiz-Martinez, Hanwen Wang, Emily Davis-Marcisak, Atul Deshpande, Aleksander S. Popel, Elana J. Fertig   +7 more
doaj   +1 more source